Scarica l'app Stockscreener
8.40
0.83%
-0.07
Dopo l'orario di chiusura:
8.32
-0.08
-0.95%
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 3.5%Should You Sell? - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Sees Large Volume IncreaseTime to Buy? - MarketBeat
H.C. Wainwright maintains buy rating on ORIC Pharmaceuticals stock By Investing.com - Investing.com Nigeria
BNP Paribas Financial Markets Buys New Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Wedbush Reiterates Outperform Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
Oric Pharma Stock Hits 3-Month High On Promising Results In Prostate Cancer Trial - MSN
Viking in PIPE Investment in ORIC Pharmaceuticals - Cleary Gottlieb
Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know - Yahoo Finance
ProShare Advisors LLC Increases Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:ORIC) - MarketBeat
Research Analysts Set Expectations for ORIC FY2025 Earnings - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpStill a Buy? - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down – Here’s What Happened - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap DownWhat's Next? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC), Oric Pharmaceuticals (ORIC) and Kestra Medical Technologies Ltd. (KMTS) - The Globe and Mail
ORIC-944 shows promise in combination with AR inhibitors in mCRPC - Urology Times
Deutsche Bank AG Has $464,000 Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Given “Outperform” Rating at Wedbush - Defense World
Traders Buy Large Volume of ORIC Pharmaceuticals Call Options (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials - MSN
ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study - sharewise
ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital - Benzinga
ORIC Pharmaceuticals shares surge on promising trial data By Investing.com - Investing.com South Africa
ORIC Pharmaceuticals shares surge on promising trial data - Investing.com Australia
ORIC Pharma jumps on promising data from prostate cancer drug trial - TradingView
Oric Pharmaceuticals (ORIC) Shows Promising Results in Cancer Drug Trial | ORIC Stock News - GuruFocus
ORIC Pharmaceuticals secures $125 million in private placement By Investing.com - Investing.com South Africa
ORIC Pharma's Prostate Cancer Drug Shows Encouraging Early Results; Upcoming Milestones Ahead - RTTNews
ORIC Pharmaceuticals (ORIC) Secures $125M in Private Stock Sale - GuruFocus
Transcript : ORIC Pharmaceuticals, Inc.Special Call - marketscreener.com
Oric Pharmaceuticals (ORIC) Secures $125M in Private Placement | - GuruFocus
ORIC Pharmaceuticals (ORIC) Secures $125M to Advance R&D - GuruFocus
ORIC Pharmaceuticals secures $125 million in private placement - Investing.com India
Oric Pharmaceuticals (ORIC) Reveals Promising Phase 1b Trial Dat - GuruFocus
Oric Pharmaceuticals (ORIC) Reveals Promising Phase 1b Trial Data for Prostate Cancer Treatment | ORIC Stock News - GuruFocus
ORIC® Pharmaceuticals Announces Potentially Best-In-Class Prelim - GuruFocus
ORIC® Pharmaceuticals Announces $125 Million Private Placement F - GuruFocus
ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC - The Manila Times
ORIC Lands Massive $125M Investment Led by SR One, Extending Runway Through Critical Phase 3 Cancer Trial - Stock Titan
ORIC Pharmaceuticals Showcases Cancer Drug Pipeline at Jefferies and Goldman Healthcare Conferences - Stock Titan
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences | ORIC Stock News - GuruFocus
ORIC Pharmaceuticals: Promising Growth Potential with Superior Safety Profile and Strong Financial Position - TipRanks
ORIC® Pharmaceuticals to Present Initial Data from Phase 1b - GlobeNewswire
ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC - The Manila Times
New Clinical Data: ORIC-944 Combination Therapy Shows Early Results for Advanced Prostate Cancer - Stock Titan
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Holdings Lowered by Frazier Life Sciences Management L.P. - MarketBeat
Janus Henderson Group PLC Acquires New Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
0.87%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):